Details
|
Nuvelo, Inc. is a biopharmaceutical company, which is focusing producing and commercialization of therapeutic products for the treatments of cancer and acute cardiovascular diseases. Nuvelo's products candidates include rNAPc2 (recombinant nematode anticoagulant protein c2), ARC183, and Alfimeprase. ARC183 is a thrombin inhibitor for use in acute anticoagulant applications, percutaneous coronary interventions, and in coronary arteries bypass graft surgeries. rNAPc2 is in 2A placebo clinical study , indicated for treatment of acute coronary disorders, such as non-ST myocardial infarction and unstable angina. Company's Alfimeprase is a blood clots dissolver and is currently in phase 3 clinical trial. Nuvelo,inc. works in collaboration and licensing with Archemix Co., Bayer healthcare AG, Kirin Brewery Corporation, and Dendreon Co. Nuvelo, Inc. was established in 1991 and it was previously called Hyseq Pharmaceuticals and changed company's name to Nuvelo, inc. in 2003. The company is based in Sunnyvale, state California. Contact www.nuvelo.com Tel#: 408-215-4000. (NASDAQ: NUVO)
|
